<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200114046123N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-01-23</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effects of adolescent health promotion training package on treatment of poly cystic ovary disease</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effects of adolescent health promotion training package on treatment of poly cystic ovary syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/45065</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: The sampling method is random cluster sampling in the educational districts of Tehran. At first Tehran are divided into five educational districts (East, West, North, South and Center). The areas in the five districts are written separately on paper and were drawn randomly. Then again, in each cluster, the girls' secondary schools are written separately on a single paper and randomly drawn. In the draw, the first school name in each district is placed in the intervention group respectively; the second school name in that district is placed in the control group (two schools in each district).</study_design>
      <phase>N/A</phase>
      <hc_freetext>poly cystic ovarian syndrome.</hc_freetext>
      <i_freetext>Intervention 1: "Intervention group:" Face-to-face teaching  polycystic ovary syndrome adolescents are conducted in eight 45-minute sessions of lecture, question and answer provided by the researcher. The adolescent health promotion package was designed based on the Nice Clinical Guidelines Model. Based on this model, the package was designed after searching the guides, books, sexual health packages of various countries as well as available articles. Then, Delphi method was used to validate the sexual health package by specialists and experts in different cities of Iran. Designed in two parts for the adolescent and adolescent lifestyle educator, the package is designed to include the most important aspects of adolescent health during education years. Intervention 2: "Control group: " The control group receive only routine care and receive no intervention and training packages. Routine care includes blood pressure control, weight measurement, blood biomarkers and ultrasound measurement.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
one report include: introduction, methods, results and discussion

When:
12 months after published manuscript

To whom:
Academic researchers are allowed access to data

Conditions:
Citing the source

Where to obtain:
Correspondence  with responsible author by email

How to obtain:
The application letter should include the name of the applicant, the use and the scientific title of the research project or article in question.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Somayeh Abdolahian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing &amp; Midwifery, Niayesh and Valiasr intersection</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985717443</zip>
        <telephone>+98 21 8820 2512</telephone>
        <email>abdolahian.s@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Nahidi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing &amp; Midwifery, intersection of Valiasr and Niayesh</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985717443</zip>
        <telephone>+98 21 8820 2512</telephone>
        <email>nahidifateme@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Written parental  and student agreement
Girls ages 14 to 18 who are single and without sexual relation
At least 2 years passed from the juvenile menarche
According to ASRM criteria, 2 items of PCOS symptoms were diagnosed
Be healthy in terms of all diseases including liver, kidney, thyroid, heart and skeletal diseases
Have not taken any female hormone or metformin medication for at least three months before entering the study
Have no smoking at least three months before the intervention
Do not use drugs or alcohol
Not have severe mental illness (which requires medication)
Do not exercise professionally or attend school sports team
Do not follow a specific diet</inclusion_criteria>
      <agemin>14 years</agemin>
      <agemax>18 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Adolescents who failed to perform 1/3 of the recommended physical activities per month for any reason
Adolescents who for any reason failed to attend 1/3 of the classes held at the school.
Adolescents who have not completed any form of physical activity and diet assessment for at least one month for any reason.
Adolescents who affected by a specific illness or need to take a particular drug after entering the plan.
Adolescents who they or their parents are reluctant to continue in the project for any reason.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E28.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Polycystic ovarian syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>"Intervention group:" Face-to-face teaching  polycystic ovary syndrome adolescents are conducted in eight 45-minute sessions of lecture, question and answer provided by the researcher. The adolescent health promotion package was designed based on the Nice Clinical Guidelines Model. Based on this model, the package was designed after searching the guides, books, sexual health packages of various countries as well as available articles. Then, Delphi method was used to validate the sexual health package by specialists and experts in different cities of Iran. Designed in two parts for the adolescent and adolescent lifestyle educator, the package is designed to include the most important aspects of adolescent health during education years.</i_keyword>
      <i_keyword>"Control group: " The control group receive only routine care and receive no intervention and training packages. Routine care includes blood pressure control, weight measurement, blood biomarkers and ultrasound measurement.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Life style modification in adolescent with poly cystic ovarian syndrome. Timepoint: before intervention, 6 and 12 after intervention. Method of measurement: diet and physical activity  questionnaire.</prim_outcome>
      <prim_outcome>Menstrual cycleregularity,. Timepoint: Before intervention and 6, 12 months after intervention. Method of measurement: Menstrual cycles are &lt;21 or more than 35 days or have &lt;8 cycles per year will be considered irregular.</prim_outcome>
      <prim_outcome>Hirsutism status. Timepoint: Before intervention and 6, 12 months after intervention. Method of measurement: The Ferriman–Gallwey scale will be used for Hirsutism status; a score of 1–4 is given for nine areas of the body. A total score &lt;9 is considered normal, a score of 9–15 indicates mild Hirsutism, and a score &gt;15 indicates moderate or severe Hirsutism.</prim_outcome>
      <prim_outcome>Anthropometric index. Timepoint: Before intervention and 6, 12 months after intervention. Method of measurement: weight,height, waist, and hip circumstance.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Blood bio markers. Timepoint: before intervention and  after 12 months. Method of measurement: Blood test.</sec_outcome>
      <sec_outcome>Sonography Items. Timepoint: before intervention and  after 12 months. Method of measurement: Transabdominal Sonography.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-07-02</approval_date>
        <contact_name>Ethics committee of  Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>7th Floor, Bldg No.2 SBUMS, Arabi Ave, Daneshjoo Blvd, Velenjak, Tehran, Iran. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
